跳至主要内容
临床试验/EUCTR2014-000627-24-HU
EUCTR2014-000627-24-HU进行中(未招募)不适用

A follow-up study to examine the presence of anti-human growth hormone antibodies following a randomised, open-label, parallel-group, multi-centre trial (FE 999905 CS07) in which the efficacy and safety of 12 months’ treatment with one daily dose of ZOMACTON were compared to one daily dose of GENOTROPI

Ferring Pharmaceuticals A/S0 个研究点目标入组 46 人开始时间: 2014年5月14日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
46

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Previous participation in trial FE 999905 CS07 and presence of anti-hGH antibodies at any post-dosing visit throughout the 12-month treatment period
  • - Signed informed consent and obtained assent according to local rules and practice
  • - Information on medical history, concomitant medications, and growth hormone therapy since completion of trial FE 999905 CS07
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 46
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • There are no pre-defined exclusion criteria in this study.

研究者

相似试验